9/16/14 - Medscape Medical News recently reviewed the stem cell research presented at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS).  Read the full article below.


9/10/14 - EMD Serono and Accelerated Cure Project Launch Collaborative Research Program to Optimize Treatment and Understand Progression of Multiple Sclerosis.  Tisch MS Research Center of New York is proud to be a participating site in this longitudinal clinical research study.  For more information, contact (212) 265-8070 and ask to speak with a Clinical Research Assistant. Read the full press release here:


By Dr. James W. Stark

The FDA has approved Plegridy, which is a pegylated (long-acting) formulation of Avonex. Plegridy is administered every other week, subcutaneously (instead of intramuscularly) but is otherwise similar to Avonex in terms of efficacy and side effect profile. This medication should become available to patients soon. If you would like to learn more, please bring it up with your physician at your next office visit. 

 


Patients with multiple sclerosis can exhibit worsened symptoms for a few different reasons.  As physicians, we use certain terms differently from how they are used in regular speech and this can generate some confusion. For example, we reserve the term ‘relapse’ for new or worsened symptoms, which are due to new inflammatory MS activity in the brain or spinal cord.


The European Commission has granted Biogen approval for their pegylated (long-acting) formulation of Avonex, called Plegridy. Plegridy has the same active ingredients as Avonex, but is administered subcutaneously (instead of intramuscularly) and every other week (instead of every week). Studies have shown equivalent efficacy in preventing MS disease activity and a similar side effect profile when compared to...


A Tip From IMSMP Naturopathic Doctor, Dr. Deneb Bates: Many patients have asked "Should I decrease the dose of my Vitamin D supplement during the summer months?"


We are pleased to announce, Dr. Saud A. Sadiq, Director of the International Multiple Sclerosis Management Practice (IMSMP) and Tisch MS Research Center of New York (Tisch MSRCNY) has been elected a Fellow Member of the American Academy of Neurology (AAN). This outstanding achievement recognizes the contributions Dr. Sadiq has made to the Academy and to the neurology community.


Congratulations to Dr. Saud A. Sadiq for his neurology listing in New York Magazine's Best Doctors issue 2014!

http://nymag.com/bestdoctors/


An article was recently published in the journal, Neurology, which compared the cognitive function of 20 patients with MS who smoked cannabis to 19 MS patients who did not smoke. The patients were matched for a variety of variables such as age, education level, etc… The authors found that cannabis users performed worse on a variety of cognitive tasks and there were also some differences in brain activity, as...


Pages

Subscribe to IMSMP Weekly Update